Leaving the Glucocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?
- PMID: 28774376
- DOI: 10.1016/j.jacc.2017.06.037
Leaving the Glucocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?
Keywords: biomarkers; cangliflozin; empagliflozin; liraglutide.
Comment on
-
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.J Am Coll Cardiol. 2017 Aug 8;70(6):704-712. doi: 10.1016/j.jacc.2017.06.016. Epub 2017 Jun 12. J Am Coll Cardiol. 2017. PMID: 28619659 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
